Board Meeting Details
The Board of Directors meeting was held on July 31, 2026, commencing at 02:00 PM and concluding at 03:40 PM.
Key Decisions Approved
- Approved the Un-Audited Standalone Financial Results of the Company for the first quarter ended June 30, 2026, along with the Limited Review Report issued by the Statutory Auditors
- Considered and approved the Notice convening the 34th Annual General Meeting (AGM) of the Company, along with the Directors' Report and Corporate Governance Report for the financial year ended March 31, 2026
- Fixed the date, time and venue of the 34th AGM as Wednesday, September 30, 2026, at 10:00 A.M., to be held at the Registered Office of the Company
- Appointed Mr. VBSS Prasad, Practicing Company Secretary, as Scrutinizer for conducting the remote e-voting process and voting at the venue of the 34th AGM
Financial Results for Quarter Ended June 30, 2026
Income Statement (₹ in Lakhs)
Revenue from Operations: ₹0.00 (compared to ₹32.19 in Q1 FY2026 and ₹0.00 in Q4 FY2026)
Other Income: ₹0.00 (compared to ₹1.31 in Q1 FY2026 and ₹0.02 in Q4 FY2026)
Total Revenue: ₹0.00 (compared to ₹33.50 in Q1 FY2026 and ₹0.02 in Q4 FY2026)
Expenses:
- Employee Benefit Expenses: ₹5.72
- Selling Expenses: ₹0.01
- Other Expenses: ₹5.56
- Total Expenses: ₹11.29
Profit/(Loss) before tax: (₹11.29) loss (compared to ₹1.40 profit in Q1 FY2026 and (₹11.66) loss in Q4 FY2026)
Tax Expenses: ₹0.00
Profit/(Loss) for the period: (₹11.29) loss (compared to ₹1.40 profit in Q1 FY2026 and (₹11.66) loss in Q4 FY2026)
Total Comprehensive Income for the period: (₹11.29) loss
Capital Structure
Paid-up Equity Capital: ₹205.02 lakhs (Face value of ₹2/- each, unchanged from previous periods)
Reserves excluding Revaluation Reserves: Not specified for current period (was (₹122.42) as per previous accounting year balance sheet)
Earnings Per Share
Basic EPS: (₹0.11) loss per equity share
Diluted EPS: (₹0.11) loss per equity share
Auditor Review
Statutory Auditors VASG & ASSOCIATES issued an unmodified review report dated July 31, 2026, stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410.
Additional Information
- The results were reviewed by the Audit Committee and approved by the Board of Directors
- The company operates in one reportable business segment: Trading of Pharmaceuticals
- Segment reporting as per Ind AS 108 is not applicable
- Results are available on BSE Limited website and company's website
- Figures for previous periods have been rearranged/reclassified wherever necessary